Join Medicilon at the Discovery on Target (DOT) 2023——The Industry's Preeminent Event on Novel Drug Targets and Technologies

Ready to meet Medicilon at Discovery on Target (DOT) 2023?

We looks forward to meeting you from September 25-28 in Boston, MA. Medicilon is experienced with oncology drug in any preclinical phases, from hit-to-lead to IND. We provide integrated service strategies for sponsors’ oncology drug discovery and development pipelines. We aim to enhance every step in preclinical search and to deliver real time data.

Date: September 25-28, 2023

Location: Boston, MA

Medicilon Booth: 221

About Discovery on Target (DOT)

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.

20th Anniversary event of DOT brings back popular topics like immunomodulation, protein degraders, and RNA, plus new, expanded, or returning programming on transcription factors, small molecules for cancer targets, and kinases.

Overview of Medicilon R&D technology platforms

❖PROTAC

PROTACs offer a fast and reversible chemical knock-down approach to control protein function in the cell. The impact of the PROTAC platform has changed the landscape of drug discovery and development. Medicilon’s PROTAC drug discovery technology platform covers many of the popular target protein ligands. We have established an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize highly active PROTAC bispecific small molecules, which have the potential to significantly facilitate the drug development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages. Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 3 PROTAC drugs by NMPA and/or FDA and has more than 20 PROTAC projects under development.

Medicilon has:

• Know-how: > 6 years PROTACs experience

• Comprehensiveness: > 20 ongoing projects

• Talent: > 300 dedicated well-trained chemists

• Team: > 300 dedicated well-trained chemists

• Building Block: > 300 advanced linkers Available

• Scaffold: > 150 E3 ligands available including Cereblon, VHL, MDM2, IAP, etc.

❖ADC

Medicilon started ADC non-clinical research in 2014. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 13 ADC drugs by NMPA and/or FDA and has more than 10 ADC projects under development. Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins.

❖Antibody

With the development of antibody technology, antibody now presents a good development prospect. While major companies are deploying antibody product research and development, they also pay great attention to what needs to be paid attention to and considered in the biological analysis of antibody. Regulations and technical points. The Pharmaceutical Analysis Department of Medicilon Biotechnology is committed to tailoring Case by Case biological analysis methods for customers. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 17 monoclonal antibody drugs and 7 bispecific antibody drugs by NMPA, FDA, and TGA.

❖Nucleic Acid Drug

Medicilon nucleic acid drug R&D platform provides an integrated and comprehensive solution that covers drug discovery, CMC and preclinical research services. Oriented with a rigorous scientific approach, an open-minded teamwork spirit and state-of-the-art equipment, our integrated solution will help clients and partners to fulfil their research and development mission for cutting-edge and innovative nucleic acid drugs. Our service platforms include nucleic acid drug discovery, screening and preclinical research services of pharmacology, DMPK and toxicity study for both pharmaceutical companies and academic research institutions. Attributed by its fast and intuitive design of base sequences, the development of nucleic acid drugs is featured with simple materials, convenient preparation processes and affordable production costs, which will greatly shorten the drug development cycle, making it possible to customize individual treatment plans. Hence, it offers a feasible solution for rare diseases and other problems currently plagued.

❖Peptide

In the research and development of peptide drugs, the many characteristics of peptides have caused difficulties and challenges in the analysis process. In the analysis of peptide biotechnology drugs, Medicilon Biotechnology Drug Analysis Department flexibly uses ELISA, ECL, TRFIA, CLIA, IF, IP, CoIP, qPCR, FACS, ELISpot, enzymology and other methods to support cutting-edge biology Drugs such as proteins, antibodies (monoclonal antibodies, bi- or multispecific antibodies, antibody fragments), ADCs, peptides, nucleic acids, vaccines and cell gene therapy and other drugs in the early development, preclinical and clinical stages of PK/TK/Immunogenicity (Total ADA& Nab)/Biomarker&Cytokine and other research evaluation.

❖mRNA Vaccine Bioanalysis Platform

Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines， specifically the research of LNP-mRNA drugs and vaccines, accumulating rich experience. Hence we establish the bioanalysis platform for mRNA vaccines.

❖Cell & Gene Therapy

Cell & Gene therapy has developed rapidly in recent years, providing the possibility of curing many difficult-to-treat cancers. With the rapid development of gene transduction and gene modification technology, delivery vector system, cell culture technology and other fields, gene therapy has made a breakthrough, provide a better solution, concept and idea for intractable diseases (especially rare genetic diseases). Medicilon has established a one-stop research platform for the preclinical R&D of cell & gene immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed multiple preclinical projects for clients worldwide.

❖AI R&D Innovation

As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning.  Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model.  Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.

#DOT #drugdiscovery #target